Home » Topics » Regulatory » EMA

EMA
RSS

EMA gives positive opinion for hepatitis C therapy Viekirax plus Exviera

Nov. 24, 2014

Palovarotene receives EMA orphan medicinal product designation

Nov. 24, 2014

Nintedanib obtains positive opinion in European Union for the treatment of IPF

Nov. 24, 2014

Cosentyx receives positive CHMP opinion for first-line treatment of psoriasis

Nov. 24, 2014

E.U. orphan drug designation given to Xeris' soluble glucagon

Nov. 13, 2014

EMA accepts Oleogel-S10 MAA for review

Nov. 5, 2014

European COMP gives positive opinion on orphan drug designation for IVA-337 in systemic sclerosis

Nov. 4, 2014

EMA releases third and final module on influenza vaccine guidance for public consultation

Nov. 3, 2014

EMA publishes revised guideline on biosimilars

Nov. 3, 2014

T-cell immunotherapy ATIR receives EMA orphan status for acute myeloid leukemia

Oct. 31, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...